Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012

Epidemiology and Infection

Volumn 142, Issue 4, 2014, Pages 724-728

  Huygen, K ^a   Rodeghiero, C ^a   Govaerts, D ^b   Leroux Roels, I ^c   Melin, P ^d   Reynders, M ^e   Van Der Meeren, S ^f   Van Den Wijngaert, S ^g   Pierard, D ^f  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b Centre Hospitalier Universitaire de Charleroi   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e AZ Sint Jan   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Pertussis (whooping cough); vaccine preventable diseases

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; BACTERIUM ANTIBODY;

ADULT; ARTICLE; BELGIAN; BORDETELLA PERTUSSIS; ELISA KIT; ETHNIC GROUP; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; POPULATION RESEARCH; RANDOM SAMPLE; SEROPREVALENCE; ZOONOSIS; BELGIUM; BLOOD; IMMUNOLOGY; YOUNG ADULT; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHIC DISTRIBUTION; VIRION;

ADULT; ANTIBODIES, BACTERIAL; BELGIUM; BORDETELLA PERTUSSIS; HUMANS; PERTUSSIS TOXIN; WHOOPING COUGH; YOUNG ADULT;

EID: 84901701361     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813002458     Document Type: Article

References (14)

1. Zepp F, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infectious Diseases 2011; 11: 557-570.
2. Vincent M, et al. Pertussis serodiagnosis in Belgium from 1990 to 2009. Clinical and Vaccine Immunology 2011; 18: 588-594.
3. Hallander HO, et al. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2009; 117: 797-807.
4. Van der Wielen M, et al. Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine 2003; 21: 2412-2417.
5. Theeten H, et al. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphteria and tetanus in Belgium. Epidemiology and Infection 2011; 139: 494-504.
6. Olin P, et al. Randomized controlled trial of twocomponent, three-component and five-component acellular pertussis vaccines compared to whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350: 1569-77.
7. Hendrikx L, et al. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 2009; 27: 6530-6536.
8. Wiley K, et al. Sources of pertussis infection in young childen: a review of key evidence informing targeting of the cocoon strategy. Vaccine 2013; 31: 618-625.
9. Wendelboe AM, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatric Infections Disease Journal 2005; 24: S58-S61.
10. de Greeff SC, et al. Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010; 5:e14183.
11. Aguas R, Goncalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infectious Diseases 2006; 6: 112-117.
12. DeMaria A, Lett SM. Vaccinate the Village. Clinical Infectious Diseases 2010; 50: 1346-1348.
13. Forsyth KD, et al. Global Pertussis Initiative: new pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clinical Infectious Diseases 2004; 39: 1802-1809.
14. Munoz F. Maternal immunization: an update for pediatricians. Pediatric Annals 2013; 42: 153-158.